



## **Agenus to Report First Quarter 2015 Financial Results on April 23, 2015; Conference Call to Follow**

April 20, 2015

LEXINGTON, Mass.--([BUSINESS WIRE](#))--Agenus Inc. (NASDAQ: AGEN) will release its first quarter 2015 financial results before the market opens on Thursday, April 23, 2015. Agenus executives will host a conference call at 11 a.m. Eastern Time the same day.

To access the live call, dial 866-233-4585 (U.S.) or 416-640-5946 (international). The call will also be webcast and will be accessible from the company's website at [www.agenusbio.com/webcast/](http://www.agenusbio.com/webcast/). A replay will be available on the company's website approximately two hours after the call and will remain available for 60 days. The replay number is 866-245-6755 (U.S.) or 416-915-1035 (international), and the access code is 601129.

### **About Agenus**

Agenus is an immunology company developing a series of immuno-oncology CPMs, heat shock protein peptide-based vaccines and immune adjuvants. These programs are supported by three separate technology platforms. Agenus' checkpoint modulator programs target GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company's proprietary discovery engine Retrocyte Display™ is used to generate fully human and humanized therapeutic antibody drug candidates. The Retrocyte Display platform uses a high-throughput approach incorporating IgG format human antibody libraries expressed in mammalian B-lineage cells. Agenus recently acquired a powerful yeast antibody display platform termed SECANT, developed by Celexion. SECANT allows rapid generation of soluble, full-length human antibodies. It and 4-Ab's mammalian antibody display platform have complementary strengths and further bolster Agenus' abilities to generate and optimize fully human monoclonal antibodies. Agenus' heat shock protein peptide-based vaccines have completed Phase 2 studies in newly diagnosed glioblastoma multiforme, and in the treatment of herpes simplex viral infection; the heat shock protein-based vaccine platform can generate personalized as well as off the shelf products. The company's QS-21 Stimulon® adjuvant platform is extensively partnered with GlaxoSmithKline and Janssen Sciences Ireland UC and includes several candidates in Phase 2 trials, as well as shingles and malaria vaccines which have successfully completed Phase 3 clinical trials. For more information, please visit [www.agenusbio.com](http://www.agenusbio.com), or connect with the company on Facebook, LinkedIn, Twitter and Google+.

### **Forward-Looking Statement**

*This press release contains forward-looking statements, including statements regarding the Company's anticipated timing for releasing its first quarter 2015 financial results. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or annual report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.*

### **Contact:**

Media:

BMC Communications  
Brad Miles, 646-513-3125  
[bmiles@bmccommunications.com](mailto:bmiles@bmccommunications.com)

or

Investors:

Argot Partners  
Andrea Rabney/Jamie Maarten, 212-600-1902  
[andrea@argotpartners.com](mailto:andrea@argotpartners.com)  
[jamie@argotpartners.com](mailto:jamie@argotpartners.com)